Stable, tested and effective staphylococcal vaccine
Immunology Laboratories, Inc.
Mastitis is ranked second after infertility as a main reason for culling cows. 20-50% of dairy cows are treated for infection in Europe and the USA
The MRSA is emerging on the companion animals (dogs, cats and horses) as well as on swine herds through the whole word. The isolated MRSA strains are identical with the human MRSA strains. This problem, including a new MRSA strain ST 398 originally isolated from the swine herds and already isolated on the horses and human including kindergarten children, is representing another emerging challenge to the human and animal health.
In the U.S.A. the S. aureus mastitis comprise a total of 10-12% of all clinical mastitis. It creates the yearly cost/loss of the $2 billion to the American dairy industry. Longitudinal studies of clinical mastitis caused by S. aureus detected in the milk of dairy cattle worldwide was 26% contaminated milk in Tanzania to 23% at Netherland as of the year 2000. Therefore we are facing the global problem. The worldwide number of dairy cows as of the year 2003 was more then 238 million. Another dairy animal, which is suffering with the same S. aureus mastitis problem, is the water buffalo. At the year of 2005 it was 130 million water buffalos living world wide, more then 60% of the animals in the Pakistan and India.
ImmLab products are staphylococcal-lysate-based vaccines for prevention and treatment of staphylococcal infections in humans, companion animals, and farm animals. ImmLab staphylococcal vaccines are created by introducing the genome of the staphylococcal bacteriophage into the staphylococcal cell, resulting in the production of highly immunogenic vaccine comprised of all staphylococcal proteins and cell-wall components.
The vaccine can treat and prevent the most common skin infections in companion and farm animals. These infections are caused by the staphylococcus. The animal contact leads to human colonization, infection and further spread. Therefore, the use of this vaccine will affect both veterinary and human medicine.
Dairy-cow mastitis vaccine
The vaccine will prevent dairy-cow mastitis caused by the staphylococcus. The enormous economic impact of this one disease to the American dairy farmer and, subsequently, to the consumer is well established. Current therapies (antibiotics, vaccines, management practices) are not sufficiently effective. Vaccination with this product before infection will create herd immunity, saving millions of dollars annually to this industry.
Human staphylococcal vaccine
The vaccine is designed for prevention and treatment of human staphylococcal infections. It is non-toxic, does not generate bacterial resistance, and is affordable. It will address an urgent and ever growing need in vulnerable populations, where collectivization occurs (i.e., the military, hospitals, nursing homes, and schools). A key target for our technology are S.aureus infected individuals and individuals at increased risk of exposure to and infection by S. aureus strains, including methicillin-resistant strains (MRSA), vancomycin-intermidiate strains (VISA) and vancomycin-resistant strains (VRSA). ImmLab technology would have a role for pre-treatment of those facing elective surgery or any other non-urgent invasive treatment.
Copyright © Immunology Laboratories, Inc. 2019 All rights reserved.